Maxigen Biotech (Taiwan) Performance
| 1783 Stock | TWD 44.60 1.15 2.65% |
The company secures a Beta (Market Risk) of -0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Maxigen Biotech are expected to decrease at a much lower rate. During the bear market, Maxigen Biotech is likely to outperform the market. At this point, Maxigen Biotech has a negative expected return of -0.0594%. Please make sure to verify Maxigen Biotech's value at risk, skewness, and the relationship between the maximum drawdown and potential upside , to decide if Maxigen Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Maxigen Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Maxigen Biotech is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 209.8 M | |
| Total Cashflows From Investing Activities | -2.8 M |
Maxigen |
Maxigen Biotech Relative Risk vs. Return Landscape
If you would invest 4,655 in Maxigen Biotech on September 1, 2024 and sell it today you would lose (195.00) from holding Maxigen Biotech or give up 4.19% of portfolio value over 90 days. Maxigen Biotech is generating negative expected returns and assumes 1.3186% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than Maxigen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Maxigen Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Maxigen Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Maxigen Biotech, and traders can use it to determine the average amount a Maxigen Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.045
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1783 |
Estimated Market Risk
| 1.32 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Maxigen Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Maxigen Biotech by adding Maxigen Biotech to a well-diversified portfolio.
Maxigen Biotech Fundamentals Growth
Maxigen Stock prices reflect investors' perceptions of the future prospects and financial health of Maxigen Biotech, and Maxigen Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Maxigen Stock performance.
| Return On Equity | 0.0926 | |||
| Return On Asset | 0.0454 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 84.7 M | |||
| Price To Earning | 33.55 X | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 6.63 X | |||
| Revenue | 511.98 M | |||
| EBITDA | 130.56 M | |||
| Cash And Equivalents | 390.34 M | |||
| Cash Per Share | 5.62 X | |||
| Total Debt | 16.62 M | |||
| Debt To Equity | 1.50 % | |||
| Book Value Per Share | 14.75 X | |||
| Cash Flow From Operations | 117.59 M | |||
| Earnings Per Share | 1.23 X | |||
| Total Asset | 1.27 B | |||
| Retained Earnings | (14 M) | |||
| Current Asset | 623 M | |||
| Current Liabilities | 63 M | |||
About Maxigen Biotech Performance
Evaluating Maxigen Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Maxigen Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Maxigen Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and cosmeceutical skincare products in Taiwan and internationally. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan, Taiwan. MAXIGEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.Things to note about Maxigen Biotech performance evaluation
Checking the ongoing alerts about Maxigen Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Maxigen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Maxigen Biotech generated a negative expected return over the last 90 days | |
| About 52.0% of the company shares are owned by insiders or employees |
- Analyzing Maxigen Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Maxigen Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Maxigen Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Maxigen Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Maxigen Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Maxigen Biotech's stock. These opinions can provide insight into Maxigen Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Maxigen Stock Analysis
When running Maxigen Biotech's price analysis, check to measure Maxigen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maxigen Biotech is operating at the current time. Most of Maxigen Biotech's value examination focuses on studying past and present price action to predict the probability of Maxigen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maxigen Biotech's price. Additionally, you may evaluate how the addition of Maxigen Biotech to your portfolios can decrease your overall portfolio volatility.